2022 World Conference on Lung Cancer (ePosters)-EP08.01-058. Access to Immunotherapy in Control Arms of Pivotal First Line Immunotherapy Trials in Metastatic Non-Small Cell Lung Cancer

EP08.01-058. Access to Immunotherapy in Control Arms of Pivotal First Line Immunotherapy Trials in Metastatic Non-Small Cell Lung Cancer

Back to course

Pdf Summary

Immunotherapy has shown significant improvements in the outcomes of patients with metastatic non-small cell lung cancer (NSCLC). FDA-approved drugs like Pembrolizumab and Nivolumab have been effective in previously treated recurrent/metastatic NSCLC. First-line clinical trials have also demonstrated better outcomes compared to chemotherapy. However, the access to subsequent immunotherapy in the control arm of these trials is not well-known.<br /><br />To understand this, researchers reviewed first-line immunotherapy trials in NSCLC that led to regulatory approval in the US. They analyzed publications, trial protocols, and supplementary indices to determine the percentage of patients in the control arm who received any subsequent therapy, including immunotherapy.<br /><br />The results showed that out of the 3339 patients who received chemotherapy in the control arm of these trials, 2079 (62.3%) received subsequent therapy. Among these, 1361 patients (40.8%) received subsequent immunotherapy. In other words, among the patients who received subsequent treatment, about 65.5% of them received immunotherapy.<br /><br />The study also found that the percentage of patients receiving post-protocol immunotherapy varied greatly between trials, ranging from 28.9% to 96%. Trials that had higher rates of subsequent immunotherapy in the control arm were more likely to represent clinical practice in the US at the time of the trial enrollment, providing higher-level evidence for first-line immunotherapy regimens in NSCLC.<br /><br />Overall, this study highlights the variability in access to immunotherapy in the control arm of first-line immunotherapy trials for NSCLC. The findings suggest that the level of evidence for first-line immunotherapy regimens may be higher in trials with higher rates of subsequent immunotherapy in the control arm.

Asset Subtitle

Maham Bakhtyar

Meta Tag

Speaker Maham Bakhtyar

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Immunotherapy

Metastatic non-small cell lung cancer

NSCLC

Pembrolizumab

Nivolumab

Chemotherapy

Clinical trials

Regulatory approval

Subsequent therapy

First-line immunotherapy